Skip to main content

Table 4 Conditional logistic regression models to estimate the association between quintiles of PBDEs and PBB-153 plasma levels expressed in ng/L and breast cancer risk: adjusted odds ratios (ORs) and 95% confidence intervals (CIs) (E3N cohort, N = 394)

From: Plasma concentration of brominated flame retardants and postmenopausal breast cancer risk: a nested case-control study in the French E3N cohort

ng/L plasma

  

Model 0

P trend

Model 1

P trend

Model 2

P trend

Number (%)

controls

Number (%) cases

OR [95% CI]

OR [95% CI]

OR [95% CI]

PBDE sum

197

197

      

 Q1

39(19.80)

37(18.78)

Reference

0.97

Reference

0.66

Reference

0.59

 Q2

39(19.80)

36(18.27)

0.99 [0.53; 1.84]

 

1.09 [0.52; 2.26]

 

1.14 [0.54; 2.41]

 

 Q3

40(20.30)

38(19.29)

1.01 [0.56; 1.82]

 

1.00 [0.51; 1.94]

 

1.02 [0.52; 2.00]

 

 Q4

39(19.80)

44 (22.34)

1.18 [0.64; 2.18]

 

1.20 [0.59; 2.44]

 

1.20 [0.59; 2.46]

 

 Q5

40(20.30)

42 (21.32)

1.10 [0.58; 2.08]

 

1.13 [0.54; 2.39]

 

1.21 [0.57; 2.58]

 

log-PBDE sum

  

0.98 [0.67; 1.42]

0.9

0.95 [0.62; 1.46]

0.83

0.97 [0.63; 1.50]

0.88

BDE-28

197

197

      

 Q1

39(19.80)

34 (17.26)

Reference

0.32

Reference

0.47

Reference

0.54

 Q2

39(19.80)

40 (20.30)

1.16 [0.62–2.18]

 

1.39 [0.67–2.90]

 

1.36 [0.65–2.85]

 

 Q3

40(20.30)

34 (17.26)

0.99 [0.51–1.91]

 

0.92 [0.43–1.97]

 

0.99 [0.46–2.14]

 

 Q4

39(19.80)

41 (20.81)

1.18 [0.62–2.26]

 

1.29 [0.61–2.72]

 

1.32 [0.63–2.80]

 

 Q5

40(20.30)

48 (24.37)

1.36 [0.72–2.53]

 

1.33 [0.65–2.70]

 

1.27 [0.62–2.60]

 

log-BDE-28

  

1.04 [0.80; 1.37]

0.75

1.00 [0.74; 1.35]

0.98

0.97 [0.72; 1.33]

0.87

BDE-47

197

197

      

 Q1

39(19.80)

41 (20.81)

Reference

0.72

Reference

0.81

Reference

0.72

 Q2

39(19.80)

34 (17.26)

0.82 [0.43–1.56]

 

0.71 [0.35–1.47]

 

0.73 [0.35–1.53]

 

 Q3

40(20.30)

38 (19.29)

0.91 [0.50–1.67]

 

0.98 [0.49–1.95]

 

1.01 [0.50–2.05]

 

 Q4

39(19.80)

40 (20.30)

0.97 [0.53–1.79]

 

0.84 [0.42–1.67]

 

0.83 [0.41–1.69]

 

 Q5

40(20.30)

44 (22.34)

1.06 [0.57–1.95]

 

1.05 [0.52–2.11]

 

1.11 [0.54–2.26]

 

log-BDE-47

  

0.94 [0.70; 1.25]

0.66

0.92 [0.66; 1.29]

0.64

0.94 [0.67; 1.32]

0.72

BDE-99

197

197

      

 Q1

39(19.80)

31 (15.74)

Reference

0.55

Reference

0.66

Reference

0.66

 Q2

39(19.80)

45 (22.84)

1.50 [0.77–2.90]

 

1.30 [0.62–2.73]

 

1.23 [0.57–2.62]

 

 Q3

40(20.30)

38 (19.29)

1.27 [0.64–2.50]

 

1.26 [0.59–2.71]

 

1.32 [0.60–2.90]

 

 Q4

39(19.80)

41 (20.81)

1.38 [0.70–2.72]

 

1.20 [0.56–2.56]

 

1.09 [0.50–2.38]

 

 Q5

40(20.30)

42 (21.32)

1.36 [0.69–2.66]

 

1.28 [0.59–2.75]

 

1.29 [0.59–2.83]

 

log-BDE-99

  

1.04 [0.78; 1.39]

0.79

1.06 [0.76; 1.48]

0.72

1.07 [0.77; 1.49]

0.69

BDE-100

197

197

      

 Q1

39(19.80)

49 (24.87)

Reference

0.53

Reference

0.41

Reference

0.46

 Q2

39(19.80)

36 (18.27)

0.71 [0.38–1.33]

 

0.56 [0.27–1.17]

 

0.59 [0.28–1.27]

 

 Q3

40(20.30)

29 (14.72)

0.54 [0.28–1.05]

 

0.42 [0.19–0.92]

 

0.42 [0.19–0.93]

 

 Q4

39(19.80)

46 (23.35)

0.93 [0.51–1.70]

 

0.91 [0.46–1.80]

 

0.87 [0.44–1.74]

 

 Q5

40(20.30)

37 (18.78)

0.68 [0.35–1.30]

 

0.53 [0.24–1.17]

 

0.58 [0.26–1.28]

 

Log-BDE100

  

0.89 [0.65; 1.20]

0.44

0.95 [0.53; 1.70]

0.85

0.97 [0.54; 1.75]

0.91

BDE-153

197

197

      

 Q1

39(19.80)

43 (21.83)

Reference

0.92

Reference

0.73

Reference

0.78

 Q2

39(19.80)

45 (22.84)

1.08 [0.58–2.01]

 

1.30 [0.63–2.68]

 

1.28 [0.62–2.67]

 

 Q3

40(20.30)

22 (11.17)

0.52 [0.26–1.01]

 

0.40 [0.17–0.90]

 

0.42 [0.18–0.98]

 

 Q4

39(19.80)

44 (22.34)

1.02 [0.56–1.87]

 

1.10 [0.55–2.22]

 

1.12 [0.55–2.29]

 

 Q5

40(20.30)

43 (21.83)

0.96 [0.52–1.76]

 

0.85 [0.42–1.74]

 

0.87 [0.43–1.79]

 

log-BDE-153

  

1.02 [0.62; 1.68]

0.94

0.95 [0.53; 1.70]

0.85

0.97 [0.54; 1.75]

0.91

BDE-154

197

197

      

 Q1

39(19.80)

35 (17.77)

Reference

0.47

Reference

0.86

Reference

0.86

 Q2

39(19.80)

38 (19.29)

1.09 [0.56–2.11]

 

0.93 [0.44–1.97]

 

0.91 [0.43–1.96]

 

 Q3

40(20.30)

38 (19.29)

1.08 [0.57–2.07]

 

1.04 [0.50–2.15]

 

1.06 [0.51–2.21]

 

 Q4

39(19.80)

43 (21.83)

1.26 [0.66–2.43]

 

1.14 [0.54–2.41]

 

1.13 [0.53–2.40]

 

 Q5

40(20.30)

43 (21.83)

1.24 [0.64–2.40]

 

1.00 [0.47–2.13]

 

1.00 [0.46–2.15]

 

log-BDE-154

  

0.99 [0.75; 1.31]

0.95

0.97 [0.70; 1.33]

0.83

0.96 [0.70; 1.33]

0.82

PBB-153

197

197

      

 Q1

39(19.80)

47 (23.86)

Reference

0.31

Reference

0.33

Reference

0.29

 Q2

39(19.80)

41 (20.81)

0.90 [0.50–1.61]

 

0.73 [0.38–1.41]

 

0.67 [0.34–1.31]

 

 Q3

40(20.30)

29 (14.72)

0.58 [0.31–1.11]

 

0.49 [0.23–1.07]

 

0.48 [0.22–1.06]

 

 Q4

39(19.80)

51 (25.89)

1.06 [0.57–1.97]

 

0.96 [0.47–1.96]

 

0.92 [0.45–1.90]

 

 Q5

40(20.30)

29 (14.72)

0.58 [0.29–1.13]

 

0.53 [0.24–1.17]

 

0.50 [0.22–1.13]

 

log-PBB-153

  

1.02 [0.62; 1.68]

0.94

0.95 [0.53; 1.70]

0.85

0.97 [0.54; 1.75]

0.91

  1. Model 0: crude estimates;
  2. Model 1: adjusted for total plasma lipid content (ng/L, continuous), smoking status (never vs. ever), physical activity measured in metabolic equivalent tasks (MET)-hour/week (< 35 vs. ≥35), education (≤ 12 years, 12 to 14 years, > 14 years), personal history of benign breast disease (no vs. yes), and family history of breast cancer (none, in first-degree relatives, in extended relatives), parity and age at first full-term pregnancy (FFTP) (no children, 1 or 2 children and < 30 years old at FFTP, ≥3 children and < 30 years old at FFTP, ≥ 30 years old at FFTP), total breastfeeding duration (never, ≤6 or > 6 months), age at menarche (< 13 years vs. ≥ 13 years), current use of menopausal hormone therapy (pre-menopausal, yes, no), and use of oral contraceptives (ever vs. never), menopausal status and age at menopause (pre-menopausal, menopause before age 51, menopause at age 51 or later);
  3. Model 2: Model 1 + adherence score to the Healthy and the Western dietary patterns (above vs. below the median)